Fresenius Medical Care Ventures

ExThera

ExThera Medical is developing revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections and pathogen-reduction in blood banking.

www.extheramedical.com

Corvidia

Corvidia Therapeutics Inc. is a clinical stage biotechnology company based in Waltham, Massachusetts pioneering the next generation of cardiovascular and cardio-renal therapies.

www.corvidiatx.com 

Modulated Imaging

Modulated Imaging is developing and marketing devices for determining oxygenation levels in superficial tissues for patients with potential circulatory compromise.

www.modulatedimaging.com

Vectorious Medical Technologies

Vectorious Medical Technologies has developed an implantable microcomputer-based system that enables optimal management of heart failure patients using direct, daily left-atrial pressure (LAP) measurements.

www.vectoriousmedtech.com

Florian Jehle 
Managing Director
LinkedIn profile

Alexandra Dambeck
Managing Director
LinkedIn profile

Dr. Peter Hennke
Managing Director
LinkedIn profile

Al Wiegman
Head, Fresenius Medical Care Ventures
LinkedIn profile

Dr. Andreas Wüpper
Director Investments Europe
LinkedIn profile

John Viero
Regional Director Product and Marketing Innovation
LinkedIn profile

Revital (Tali) Hirsch
Senior Investment Associate
LinkedIn profile

Fresenius Medical Care Ventures invests in Israeli medical device company

Fresenius Medical Care Ventures, the venture capital unit of Fresenius Medical Care, announced today that it has invested $2 million in the Series B financing round for Vectorious Medical Technologies (“Vectorious”). The Israeli medical device company raised more than $10 million in this financing round, including a recent grant from the European Union’s Horizon 2020 flagship research and development program.

Vectorious has developed the V-LAP, a first of its kind in-heart microcomputer for left-atrial pressure monitoring. Data from this device is transmitted wirelessly to clinicians, enabling heart failure patients to be managed effectively before their disease advances.

The Series B financing will accelerate Vectorious’ ongoing R&D programs, as well as CE Mark and FDA regulatory approval initiatives.

read full press release 

Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work

Waltham, MA, April 25, 2018 — Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.

Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics Research and Development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round.

read full press release